CLINICAL PEDIATRIC ONCOLOGY HAEMATOLOGY



	Clinical Trials Patient Worksheet Questions to ask your doctor if you are thinking about taking part in a clinical trial.

	State Laws Regarding Clinical Trials Coverage Does your state have laws about insurance coverage of clinical trials? Find out here.

Other Clinical Trials Web Sites The following web sites offer information and services to help you find a clinical trial that is right for you.

	Cancer Trials Help The nonprofit organization Coalition of Cancer Cooperative Groups is the voice for cancer clinical trials. This web site provides information to help patients understand why clinical trials are a treatment option and learn about the clinical trial process.

	National Cancer Institute (NCI) Physician Data Query (PDQ) This web site lists more than 1,800 NCI-sponsored cancer clinical trials, and explains what to do when you find one that you think is right for you.

	Children’s Oncology Group (COG) The COG children’s cancer centers offer your child the most up-to-date-treatment through participation in clinical trials, no matter where you live. Member institutions are located in almost every state, at more than 238 medical centers.

Supported by
CLINICAL PEDIATRIC ONLINE

Yudhasmara Foundation

JL Taman Bendungan Asahan 5 Jakarta Indonesia 102010

phone : 62(021) 70081995 – 5703646

email : judarwanto@gmail.com,

http://clinicalpediatric.wordpress.com/

Clinical and Editor in Chief :

DR WIDODO JUDARWANTO

The 50 Most-Frequently Read Articles in J Clin Oncol during April 2009

clinicalpediatric — Fri, 05 Jun 2009 08:30:27 +0000

Most-read rankings are recalculated at the beginning of the month and are based on full-text and pdf views.

1.	Mark G. Kris, Paul J. Hesketh, Mark R. Somerfield, Petra Feyer, Rebecca Clark-Snow, James M. Koeller, Gary R. Morrow, Lawrence W. Chinnery, Maurice J. Chesney, Richard J. Gralla, Steven M. Grunberg
		American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
		J. Clin. Oncol. Jun 20, 2006; 24: 2932-2947. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


2.	Mohammad Jahanzeb
		Continuing Trastuzumab Beyond Progression
		J. Clin. Oncol. Apr 20, 2009; 27: 1935-1937. (In “EDITORIALS”) [Full Text] [PDF]


3.	Stephen Staal, Michael J. O”Connell, Carmen J. Allegra
		The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss or Bust?
		J. Clin. Oncol. Apr 01, 2009; 27: 1545-1548. (In “Comments and Controversies”) [Full Text] [PDF]


4.	Gunter von Minckwitz, Andreas du Bois, Marcus Schmidt, Nicolai Maass, Tanja Cufer, Felix E. de Jongh, Eduard Maartense, Christoph Zielinski, Manfred Kaufmann, Wolfgang Bauer, Klaus H. Baumann, Michael R. Clemens, Ralph Duerr, Christoph Uleer, Michael Andersson, Robert C. Stein, Valentina Nekljudova, Sibylle Loibl
		Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
		J. Clin. Oncol. Apr 20, 2009; 27: 1999-2006. (In “Breast Cancer”) [Abstract] [Full Text] [PDF]


5.	Stephen Jones, Frankie Ann Holmes, Joyce O”Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja, Kristi J. McIntyre, John E. Pippen, James H. Bordelon, Robert L. Kirby, John Sandbach, William J. Hyman, Donald A. Richards, Robert G. Mennel, Kristi A. Boehm, Wally G. Meyer, Lina Asmar, Daniel Mackey, Stefan Riedel, Hyman Muss, Michael A. Savin
		Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
		J. Clin. Oncol. Mar 10, 2009; 27: 1177-1183. (In “Breast Cancer”) [Abstract] [Full Text] [PDF]


6.	Anne S. Tsao, Ignacio Wistuba, Jack A. Roth, Hedy Lee Kindler
		Malignant Pleural Mesothelioma
		J. Clin. Oncol. Apr 20, 2009; 27: 2081-2090. (In “REVIEW ARTICLES”) [Abstract] [Full Text] [PDF]


7.	Howard Hochster, Edie Weller, Randy D. Gascoyne, Thomas M. Habermann, Leo I. Gordon, Theresa Ryan, Lijun Zhang, Natalia Colocci, Stanley Frankel, Sandra J. Horning
		Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
		J. Clin. Oncol. Apr 01, 2009; 27: 1607-1614. (In “Lymphoma and Myeloma”) [Abstract] [Full Text] [PDF]


8.	Carmen J. Allegra, J. Milburn Jessup, Mark R. Somerfield, Stanley R. Hamilton, Elizabeth H. Hammond, Daniel F. Hayes, Pamela K. McAllister, Roscoe F. Morton, Richard L. Schilsky
		American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
		J. Clin. Oncol. Apr 20, 2009; 27: 2091-2096. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


9.	Eric Winer, Julie Gralow, Lisa Diller, Beth Karlan, Patrick Loehrer, Lori Pierce, George Demetri, Patricia Ganz, Barnett Kramer, Mark Kris, Maurie Markman, Robert Mayer, David Pfister, Derek Raghavan, Scott Ramsey, Gregory Reaman, Howard Sandler, Raymond Sawaya, Lynn Schuchter, John Sweetenham, Linda Vahdat, Richard L. Schilsky
		Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
		J. Clin. Oncol. Feb 10, 2009; 27: 812-826. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


10.	Stephen Chan, Gilles Romieu, Jens Huober, Thierry Delozier, Michele Tubiana-Hulin, Andreas Schneeweiss, Ana Lluch, Antonio Llombart, Andreas du Bois, Rolf Kreienberg, Jose Ignacio Mayordomo, Antonio Antón, Mark Harrison, Alison Jones, Eva Carrasco, A. Thareau Vaury, Bente Frimodt-Moller, Pierre Fumoleau
		Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
		J. Clin. Oncol. Apr 10, 2009; 27: 1753-1760. (In “Breast Cancer”) [Abstract] [Full Text] [PDF]

11.	Martin Reck, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, Vera Gorbounova, Vera Hirsh, Natasha Leighl, Jörg Mezger, Venice Archer, Nicola Moore, Christian Manegold
		Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
		J. Clin. Oncol. Mar 10, 2009; 27: 1227-1234. (In “Thoracic Oncology”) [Abstract] [Full Text] [PDF]


12.	Lyndsay Harris, Herbert Fritsche, Robert Mennel, Larry Norton, Peter Ravdin, Sheila Taube, Mark R. Somerfield, Daniel F. Hayes, Robert C. Bast
		American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
		J. Clin. Oncol. Nov 20, 2007; 25: 5287-5312. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


13.	Bruce Cheson
		The Case Against Heavy PETing
		J. Clin. Oncol. Apr 10, 2009; 27: 1742-1743. (In “EDITORIALS”) [Full Text] [PDF]


14.	Luca Gianni, Pinuccia Valagussa
		Anthracyclines and Early Breast Cancer: The End of an Era?
		J. Clin. Oncol. Mar 10, 2009; 27: 1155-1157. (In “EDITORIALS”) [Full Text] [PDF]


15.	David P. Steensma
		The Ordinary Miracle of Cancer Clinical Trials
		J. Clin. Oncol. Apr 10, 2009; 27: 1737-1739. (In “EDITORIALS”) [Full Text] [PDF]


16.	Massimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, Dora Hatzidaki, Koji Takeda, Floris M. Wachters, Vittorio Gebbia, Egbert F. Smit, Alessandro Morabito, Ciro Gallo, Francesco Perrone, Cesare Gridelli
		Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
		J. Clin. Oncol. Apr 10, 2009; 27: 1836-1843. (In “Thoracic Oncology”) [Abstract] [Full Text] [PDF]


17.	Candyce H. Kroenke, Laura D. Kubzansky, Eva S. Schernhammer, Michelle D. Holmes, Ichiro Kawachi
		Social Networks, Social Support, and Survival After Breast Cancer Diagnosis
		J. Clin. Oncol. Mar 01, 2006; 24: 1105-1111. (In “Supportive Care and Quality of Life”) [Abstract] [Full Text] [PDF]


18.	Hans-Joachim Schmoll, Dirk Arnold
		When Wishful Thinking Leads to a Misty-Eyed Appraisal: The Story of the Adjuvant Colon Cancer Trials With Edrecolomab
		J. Clin. Oncol. Apr 20, 2009; 27: 1926-1929. (In “EDITORIALS”) [Full Text] [PDF]


19.	Eitan Amir, Bostjan Seruga, Orit Freedman, Ian Tannock
		Lapatinib Plus Paclitaxel As First-Line Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Inappropriate Conclusions From a Company-Sponsored Study?
		J. Clin. Oncol. Apr 10, 2009; 27: 1919-1919. (In “Correspondence”) [Full Text] [PDF]


20.	Clive Dunne, John P. Burke, Monica Morrow, Malcolm R. Kell
		Effect of Margin Status on Local Recurrence After Breast Conservation and Radiation Therapy for Ductal Carcinoma In Situ
		J. Clin. Oncol. Apr 01, 2009; 27: 1615-1620. (In “Breast Cancer”) [Abstract] [Full Text] [PDF]

21.	David L. Page, Jean F. Simpson
		What Is Atypical Lobular Hyperplasia and What Does It Mean for the Patient?
		J. Clin. Oncol. Aug 20, 2005; 23: 5432-5433. (In “EDITORIALS”) [Full Text] [PDF]


22.	James J. Vredenburgh, Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John Sampson, Melissa Wagner, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman
		Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
		J. Clin. Oncol. Oct 20, 2007; 25: 4722-4729. (In “Neurooncology”) [Abstract] [Full Text] [PDF]


23.	Thomas J. Smith, James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, Scott B. Cantor, Jeffrey Crawford, Scott J. Cross, George Demetri, Christopher E. Desch, Philip A. Pizzo, Charles A. Schiffer, Lee Schwartzberg, Mark R. Somerfield, George Somlo, James C. Wade, James L. Wade, Rodger J. Winn, Antoinette J. Wozniak, Antonio C. Wolff
		2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
		J. Clin. Oncol. Jul 01, 2006; 24: 3187-3205. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


24.	Bruce D. Cheson, Mathias J. Rummel
		Bendamustine: Rebirth of an Old Drug
		J. Clin. Oncol. Mar 20, 2009; 27: 1492-1501. (In “REVIEW ARTICLES”) [Abstract] [Full Text] [PDF]


25.	Pier Luigi Zinzani, Vittorio Stefoni, Monica Tani, Stefano Fanti, Gerardo Musuraca, Paolo Castellucci, Enrica Marchi, Mariapaola Fina, Valentina Ambrosini, Cinzia Pellegrini, Lapo Alinari, Enrico Derenzini, Giancarlo Montini, Alessandro Broccoli, Francesco Bacci, Stefano Pileri, Michele Baccarani
		Role of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
		J. Clin. Oncol. Apr 10, 2009; 27: 1781-1787. (In “Lymphoma and Myeloma”) [Abstract] [Full Text] [PDF]


26.	Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Goksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David Gandara
		Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
		J. Clin. Oncol. Jul 20, 2008; 26: 3543-3551. (In “Thoracic Oncology”) [Abstract] [Full Text] [PDF]


27.	Carsten Bokemeyer, Igor Bondarenko, Anatoly Makhson, Joerg T. Hartmann, Jorge Aparicio, Filippo de Braud, Serban Donea, Heinz Ludwig, Gunter Schuch, Christopher Stroh, Anja H. Loos, Angela Zubel, Piotr Koralewski
		Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
		J. Clin. Oncol. Feb 10, 2009; 27: 663-671. (In “Gastrointestinal Cancer”) [Abstract] [Full Text] [PDF]


28.	Barnett S. Kramer, Karen L. Hagerty, Stewart Justman, Mark R. Somerfield, Peter C. Albertsen, William J. Blot, H. Ballentine Carter, Joseph P. Costantino, Jonathan I. Epstein, Paul A. Godley, Russell P. Harris, Timothy J. Wilt, Janet Wittes, Robin Zon, Paul Schellhammer
		Use of 5--Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
		J. Clin. Oncol. Mar 20, 2009; 27: 1502-1516. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


29.	Arlene A. Forastiere, Ashok R. Shaha
		Chemotherapy Alone for Laryngeal Preservation—Is It Possible?
		J. Clin. Oncol. Apr 20, 2009; 27: 1933-1934. (In “EDITORIALS”) [Full Text] [PDF]


30.	Gary H. Lyman, Alok A. Khorana, Anna Falanga, Daniel Clarke-Pearson, Christopher Flowers, Mohammad Jahanzeb, Ajay Kakkar, Nicole M. Kuderer, Mark N. Levine, Howard Liebman, David Mendelson, Gary Raskob, Mark R. Somerfield, Paul Thodiyil, David Trent, Charles W. Francis
		American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
		J. Clin. Oncol. Dec 01, 2007; 25: 5490-5505. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]

31.	René Adam, Dennis A. Wicherts, Robbert J. de Haas, Oriana Ciacio, Francis Lévi, Bernard Paule, Michel Ducreux, Daniel Azoulay, Henri Bismuth, Denis Castaing
		Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
		J. Clin. Oncol. Apr 10, 2009; 27: 1829-1835. (In “Gastrointestinal Cancer”) [Abstract] [Full Text] [PDF]


32.	Antonio Jimeno, Wells A. Messersmith, Fred R. Hirsch, Wilbur A. Franklin, S. Gail Eckhardt
		KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
		J. Clin. Oncol. Mar 01, 2009; 27: 1130-1136. (In “SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


33.	Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter G. Harper, David S. Alberts, Michael Friedlander, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, Chrisann Accario-Winslow, Lawrence M. Roth
		Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
		J. Clin. Oncol. Mar 20, 2009; 27: 1419-1425. (In “Gynecologic Cancer”) [Abstract] [Full Text] [PDF]


34.	Federica Di Nicolantonio, Miriam Martini, Francesca Molinari, Andrea Sartore-Bianchi, Sabrina Arena, Piercarlo Saletti, Sara De Dosso, Luca Mazzucchelli, Milo Frattini, Salvatore Siena, Alberto Bardelli
		Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
		J. Clin. Oncol. Dec 10, 2008; 26: 5705-5712. (In “Gastrointestinal Cancer”) [Abstract] [Full Text] [PDF]


35.	Martee L. Hensley, Karen L. Hagerty, Tarun Kewalramani, Daniel M. Green, Neal J. Meropol, Todd H. Wasserman, Gary I. Cohen, Bahman Emami, William J. Gradishar, R. Brian Mitchell, J. Tate Thigpen, Andy Trotti, Daniel von Hoff, Lynn M. Schuchter
		American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
		J. Clin. Oncol. Jan 01, 2009; 27: 127-145. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


36.	Egbert F. Smit, Sjaak A. Burgers, Bonne Biesma, Hans J.M. Smit, Pier Eppinga, Anne-Marie C. Dingemans, Markus Joerger, Jan H. Schellens, Andrew Vincent, Nico van Zandwijk, Harry J.M. Groen
		Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer
		J. Clin. Oncol. Apr 20, 2009; 27: 2038-2045. (In “Thoracic Oncology”) [Abstract] [Full Text] [PDF]


37.	Teruhiko Terasawa, Joseph Lau, Stéphane Bardet, Olivier Couturier, Tomomitsu Hotta, Martin Hutchings, Takashi Nihashi, Hirokazu Nagai
		Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin’s Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
		J. Clin. Oncol. Apr 10, 2009; 27: 1906-1914. (In “REVIEW ARTICLES”) [Abstract] [Full Text] [PDF]


38.	Bostjan Seruga, Ian F. Tannock
		Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes
		J. Clin. Oncol. Feb 20, 2009; 27: 840-842. (In “Comments and Controversies”) [Full Text] [PDF]


39.	Akira Inoue, Kunihiko Kobayashi, Kazuhiro Usui, Makoto Maemondo, Shoji Okinaga, Iwao Mikami, Masahiro Ando, Koichi Yamazaki, Yasuo Saijo, Akihiko Gemma, Hitoshi Miyazawa, Tomoaki Tanaka, Kenji Ikebuchi, Toshihiro Nukiwa, Satoshi Morita, Koichi Hagiwara
		First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
		J. Clin. Oncol. Mar 20, 2009; 27: 1394-1400. (In “Thoracic Oncology”) [Abstract] [Full Text] [PDF]


40.	Anton Hagenbeek
		Maintenance or Eradication of Residual Disease in Indolent Lymphoma: Where Do We Stand?
		J. Clin. Oncol. Apr 01, 2009; 27: 1540-1542. (In “EDITORIALS”) [Full Text] [PDF]

41.	Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, Randy D. Gascoyne, Lena Specht, Sandra J. Horning, Bertrand Coiffier, Richard I. Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T. Rosen, Sigrid Stroobants, T. Andrew Lister, Richard T. Hoppe, Martin Dreyling, Kensei Tobinai, Julie M. Vose, Joseph M. Connors, Massimo Federico, Volker Diehl
		Revised Response Criteria for Malignant Lymphoma
		J. Clin. Oncol. Feb 10, 2007; 25: 579-586. (In “SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


42.	Joel S. Parker, Michael Mullins, Maggie C.U. Cheang, Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu, John F. Quackenbush, Inge J. Stijleman, Juan Palazzo, J.S. Marron, Andrew B. Nobel, Elaine Mardis, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. Bernard
		Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
		J. Clin. Oncol. Mar 10, 2009; 27: 1160-1167. (In “Breast Cancer”) [Abstract] [Full Text] [PDF]


43.	Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, Karen L. Hagerty, D. Craig Allred, Richard J. Cote, Mitchell Dowsett, Patrick L. Fitzgibbons, Wedad M. Hanna, Amy Langer, Lisa M. McShane, Soonmyung Paik, Mark D. Pegram, Edith A. Perez, Michael F. Press, Anthony Rhodes, Catharine Sturgeon, Sheila E. Taube, Raymond Tubbs, Gail H. Vance, Marc van de Vijver, Thomas M. Wheeler, Daniel F. Hayes
		American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
		J. Clin. Oncol. Jan 01, 2007; 25: 118-145. (In “ASCO SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


44.	Anthony L.A. Fields, Alan Keller, Lee Schwartzberg, Stephen Bernard, Carl Kardinal, Alan Cohen, Joe Schulz, Peter Eisenberg, John Forster, Paul Wissel
		Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer
		J. Clin. Oncol. Apr 20, 2009; 27: 1941-1947. (In “Gastrointestinal Cancer”) [Abstract] [Full Text] [PDF]


45.	Hailing Lu
		FOXP3 Expression and Prognosis: Role of Both the Tumor and T Cells
		J. Clin. Oncol. Apr 10, 2009; 27: 1735-1736. (In “EDITORIALS”) [Full Text] [PDF]


46.	Pamela J. Goodwin
		Vitamin D in Cancer Patients: Above All, Do No Harm
		J. Clin. Oncol. Apr 06, 2009; doi: 10.1200/JCO.2008.20.8629. (In “EDITORIALS”) [Abstract] [PDF]


47.	Guido Sauter, James Lee, John M.S. Bartlett, Dennis J. Slamon, Michael F. Press
		Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
		J. Clin. Oncol. Mar 10, 2009; 27: 1323-1333. (In “SPECIAL ARTICLES”) [Abstract] [Full Text] [PDF]


48.	Corey J. Langer
		The “Lazarus Response” in Treatment-Naïve, Poor Performance Status Patients With Non–Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation
		J. Clin. Oncol. Mar 20, 2009; 27: 1350-1354. (In “EDITORIALS”) [Full Text] [PDF]


49.	Malcolm J. Moore, David Goldstein, John Hamm, Arie Figer, Joel R. Hecht, Steven Gallinger, Heather J. Au, Pawel Murawa, David Walde, Robert A. Wolff, Daniel Campos, Robert Lim, Keyue Ding, Gary Clark, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy Parulekar
		Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
		J. Clin. Oncol. May 20, 2007; 25: 1960-1966. (In “Gastrointestinal Cancer”) [Abstract] [Full Text] [PDF]


50.	Panos M. Fidias, Shaker R. Dakhil, Alan P. Lyss, David M. Loesch, David M. Waterhouse, Jane L. Bromund, Ruqin Chen, Maria Hristova-Kazmierski, Joseph Treat, Coleman K. Obasaju, Martin Marciniak, John Gill, Joan H. Schiller
		Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
		J. Clin. Oncol. Feb 01, 2009; 27: 591-598. (In “Thoracic Oncology”) [Abstract] [Full Text] [PDF]


Supported by *CLINICAL PEDIATRIC ONLINE* Yudhasmara Foundation JL Taman Bendungan Asahan 5 Jakarta Indonesia 102010 phone : 62(021) 70081995 – 5703646 email : judarwanto@gmail.com, http://clinicalpediatric.wordpress.com/ Clinical and Editor in Chief : DR WIDODO JUDARWANTO Copyright © 2009, Clinical Pediatric Online Information Education Network. All rights reserved.

Foundations Links : Pediatric Hematology Oncology

clinicalpediatric — Fri, 05 Jun 2009 08:27:24 +0000

Supported by
CLINICAL PEDIATRIC ONLINE

Yudhasmara Foundation

JL Taman Bendungan Asahan 5 Jakarta Indonesia 102010

phone : 62(021) 70081995 – 5703646

email : judarwanto@gmail.com,

http://clinicalpediatric.wordpress.com/

Clinical and Editor in Chief :

DR WIDODO JUDARWANTO

Complementary and Alternative Therapies

clinicalpediatric — Fri, 05 Jun 2009 08:18:41 +0000



The terms “alternative” or “complementary” are used to refer to non-traditional methods of diagnosing, preventing, or treating cancer. Many cancer patients find that these therapies relieve symptoms or side effects, ease pain, and enhance their lives during treatment. Learning About New Cancer Treatments Learning About New Ways to Prevent Cancer Complementary and Alternative Methods for Cancer Management

Guidelines For Using Complementary and Alternative Methods

Placebo Effect

	Mind, Body, and Spirit

Learn how a good attitude and healthy spirit may have positive physical effects.

	Manual Healing and Physical Touch

Get the facts about acupuncture, reflexology, and other non-traditional therapies.

	Herbs, Vitamins, and Minerals

See what both promoters and critics say about these non-traditional methods of treatment.

	Diet and Nutrition

Find out about fasting, juicing, and other dietary practices.

	Pharmacological and Biological Treatment

Can these non-traditional therapies slow or stop the growth of cancer cells? Find out more.

Supported by
CLINICAL PEDIATRIC ONLINE

Yudhasmara Foundation

JL Taman Bendungan Asahan 5 Jakarta Indonesia 102010

phone : 62(021) 70081995 – 5703646

email : judarwanto@gmail.com,

http://clinicalpediatric.wordpress.com/

Clinical and Editor in Chief :

DR WIDODO JUDARWANTO

Treatment Decision Tools

clinicalpediatric — Fri, 05 Jun 2009 08:15:11 +0000

Bladder Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Head and Neck Cancers
Hodgkin Lymphoma
Kidney Cancer
Leukemia – Adult ALL (lymphoblastic)
Leukemia – Adult AML (myelogenous)
Leukemia – Adult CML (myelogenous)
Lung Cancer – Small Cell
Lung Cancer- Non-Small Cell
Melanoma
Multiple Myeloma
Non-Hodgkin’s Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Testicular Cancer
Uterine Cancer

Supported by
CLINICAL PEDIATRIC ONLINE

Yudhasmara Foundation

JL Taman Bendungan Asahan 5 Jakarta Indonesia 102010

phone : 62(021) 70081995 – 5703646

email : judarwanto@gmail.com,

http://clinicalpediatric.wordpress.com/

Clinical and Editor in Chief :

DR WIDODO JUDARWANTO

PEDIATRIC HEMATOLOGY : British Journal of Haematology

clinicalpediatric — Fri, 05 Jun 2009 08:09:23 +0000

	Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG)	Abstract HTML PDF (234 K)
	Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma. Kang, Min H. 1; Harutyunyan, Narine 2; Hall, Connor P. 1; Papa, Rachael A. 3; Lock, Richard B. 3	Abstract HTML PDF (252 K)

Supported by
CLINICAL PEDIATRIC ONLINE

Yudhasmara Foundation

JL Taman Bendungan Asahan 5 Jakarta Indonesia 102010

phone : 62(021) 70081995 – 5703646

email : judarwanto@gmail.com,

http://clinicalpediatric.wordpress.com/

Clinical and Editor in Chief :

DR WIDODO JUDARWANTO